Qureight has raised $20.0M in a Series B round backed by Molten Ventures, a bet on the Cambridge- and London-based company’s push to speed up clinical trials through AI-driven medical imaging.
The startup operates as an end-to-end imaging CRO, offering biopharma firms a platform that automates image management and analysis for lung and heart disease-covering areas like idiopathic pulmonary fibrosis, bronchiectasis, and pulmonary hypertension. Its pitch: turn messy clinical imaging data into precision endpoints that help treatments reach market faster. The fresh capital arrives as demand for faster, more reliable trial endpoints grows, though Qureight hasn’t detailed how it will deploy the funds.
